Lino-Silva LS, León-Takahashi A, López-Basave H, Padilla-Rosciano A, Miranda-Dévora G, Granados-García M, Salcedo-Hernández R

Idioma: Español
Referencias bibliográficas: 21
Paginas: 598-604
Archivo PDF: 177.88 Kb.

RESUMEN

Tradicionalmente las clasificaciones de los carcinomas se han basado en características clínicas o patológicas. Sin embargo, en las últimas décadas, con el desarrollo de la biología molecular, cada vez más tumores se están estudiando genéticamente y en varios se han creado clasificaciones moleculares (la más estudiada y utilizada es la de cáncer de mama). El cáncer de colon y recto no es la excepción. En esta revisión corta se explica la evolución de la clasificación molecular del cáncer de colon y recto y se abordan los conclusiones consensuadas al respecto.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124(7):979-994.

2. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editores. AJCC Cancer Staging Manual. Octava edición. EE. UU.: Springer; 2010.

3. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC Cancer Staging Manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-1474.

4. Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S, et al. Colon cancer. Crit Rev Oncol Hematol. 2010;74(2):106-133.

5. Haq AI, Schneeweiss J, Kalsi V, Arya M. The Dukes staging system: a corner stone in the clinical management of colorectal cancer. Lancet Oncol. 2009;10(11):1128.

6. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor positive breast cancer on chemotherapy: a retrospective analysis of a randomized trial. Lancet Oncol. 2010;11(1):55-65.

7. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor–positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734.

8. Liu Z, Zhang XS, Zhang S. Breast tumor subgroups reveal diverse clinical prognostic power. Sci Rep. 2014;4:4002.

9. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678-5685.

10. Forda SR, Bergström R, Chlebus M, Barker R, Andersen PH. Priorities for improving drug research, development and regulation. Nat Rev Drug Discov. 2013;12(4):247-248.

11. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50(1):113-130.

12. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer. 2003;(9):695-701.

13. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011;8(12):686-700.

14. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008;10(1):13-27.

15. Marisa L, De-Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013;10(5):1-13.

16. Schlicker A, Beran G, Chresta CM, McWalter G, Pritchard A, Weston S, et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics. 2012;5(1):1-15.

17. De-Sousa-Melo F, Wang X, Jansen M, Fessler E, Trinh A, De-Rooij LP, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013;19(5) 614-618.

18. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19(5) 619-625.

19. Budinska E, Popovici V, Tejpar S, D’Ario G, Lapique N, Sikora KO, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol. 2013;231(1):63-76.

20. Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer. 2014;134(3) 552-562.

21. Guinney J, Dienstmann R, Wang X, De-Reynies A, Schlicker A, Soneson C, et al. The Consensus Molecular Subtypes of Colorectal Cancer. Nat Med. 2015;21(11):1350-1356.